Oculis (OCS) Competitors $17.50 -0.67 (-3.69%) Closing price 04:00 PM EasternExtended Trading$17.55 +0.05 (+0.29%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OCS vs. AAPG, CRNX, KYMR, MOR, HCM, RARE, ALVO, AMRX, MIRM, and CPRXShould you be buying Oculis stock or one of its competitors? The main competitors of Oculis include Ascentage Pharma Group International (AAPG), Crinetics Pharmaceuticals (CRNX), Kymera Therapeutics (KYMR), MorphoSys (MOR), HUTCHMED (HCM), Ultragenyx Pharmaceutical (RARE), Alvotech (ALVO), Amneal Pharmaceuticals (AMRX), Mirum Pharmaceuticals (MIRM), and Catalyst Pharmaceuticals (CPRX). These companies are all part of the "pharmaceutical products" industry. Oculis vs. Its Competitors Ascentage Pharma Group International Crinetics Pharmaceuticals Kymera Therapeutics MorphoSys HUTCHMED Ultragenyx Pharmaceutical Alvotech Amneal Pharmaceuticals Mirum Pharmaceuticals Catalyst Pharmaceuticals Ascentage Pharma Group International (NASDAQ:AAPG) and Oculis (NASDAQ:OCS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability. Do insiders & institutionals have more ownership in AAPG or OCS? 22.3% of Oculis shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts rate AAPG or OCS? Oculis has a consensus price target of $35.33, suggesting a potential upside of 101.90%. Given Oculis' higher possible upside, analysts plainly believe Oculis is more favorable than Ascentage Pharma Group International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ascentage Pharma Group International 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Oculis 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is AAPG or OCS more profitable? Ascentage Pharma Group International has a net margin of 0.00% compared to Oculis' net margin of -13,788.70%. Ascentage Pharma Group International's return on equity of 0.00% beat Oculis' return on equity.Company Net Margins Return on Equity Return on Assets Ascentage Pharma Group InternationalN/A N/A N/A Oculis -13,788.70%-92.95%-70.03% Does the media refer more to AAPG or OCS? In the previous week, Ascentage Pharma Group International had 9 more articles in the media than Oculis. MarketBeat recorded 9 mentions for Ascentage Pharma Group International and 0 mentions for Oculis. Oculis' average media sentiment score of 0.93 beat Ascentage Pharma Group International's score of 0.49 indicating that Oculis is being referred to more favorably in the news media. Company Overall Sentiment Ascentage Pharma Group International Neutral Oculis Positive Which has higher valuation & earnings, AAPG or OCS? Ascentage Pharma Group International has higher revenue and earnings than Oculis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAscentage Pharma Group International$134.35M26.19-$55.54MN/AN/AOculis$780K979.55-$97.43M-$2.64-6.63 SummaryAscentage Pharma Group International beats Oculis on 6 of the 11 factors compared between the two stocks. Get Oculis News Delivered to You Automatically Sign up to receive the latest news and ratings for OCS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCS vs. The Competition Export to ExcelMetricOculisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$793.35M$2.96B$5.54B$9.41BDividend YieldN/A2.46%3.75%4.03%P/E RatioN/A8.2821.0120.09Price / Sales979.55303.17433.8199.01Price / CashN/A42.5936.1658.27Price / Book9.167.678.125.65Net Income-$97.43M-$55.28M$3.25B$257.91M7 Day Performance-3.10%2.50%0.97%2.09%1 Month Performance-10.16%11.70%7.36%11.13%1 Year Performance49.83%4.89%31.31%18.40% Oculis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCSOculis1.9666 of 5 stars$17.50-3.7%$35.33+101.9%+54.9%$793.35M$780K0.002AAPGAscentage Pharma Group InternationalN/A$36.20-5.3%N/AN/A$3.15B$134.35M0.00600Lockup ExpirationCRNXCrinetics Pharmaceuticals3.353 of 5 stars$33.02+3.4%$69.50+110.5%-38.7%$3.09B$1.04M-8.64210KYMRKymera Therapeutics2.9579 of 5 stars$44.90+0.9%$59.11+31.7%-1.0%$2.92B$47.07M-14.48170Analyst UpgradeMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730HCMHUTCHMED1.0218 of 5 stars$16.23+1.2%$19.00+17.1%-8.4%$2.83B$630.20M0.001,811Positive NewsRAREUltragenyx Pharmaceutical4.3814 of 5 stars$29.23-0.9%$83.64+186.2%-37.5%$2.76B$560.23M-4.971,294Trending NewsAnalyst RevisionGap DownHigh Trading VolumeALVOAlvotech2.7275 of 5 stars$8.90+4.5%$18.00+102.2%-27.1%$2.68B$585.60M24.051,032Analyst ForecastAMRXAmneal Pharmaceuticals3.2298 of 5 stars$8.42+1.1%$11.60+37.8%+10.9%$2.64B$2.79B-210.458,100News CoverageMIRMMirum Pharmaceuticals3.7678 of 5 stars$53.28+1.2%$65.50+22.9%+37.4%$2.64B$336.89M-33.09140News CoverageCPRXCatalyst Pharmaceuticals4.8975 of 5 stars$21.62-0.9%$32.83+51.9%+26.9%$2.64B$491.73M13.7780Positive News Related Companies and Tools Related Companies AAPG Competitors CRNX Competitors KYMR Competitors MOR Competitors HCM Competitors RARE Competitors ALVO Competitors AMRX Competitors MIRM Competitors CPRX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OCS) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...GoldCo Precious Metals | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oculis Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Oculis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
